|
Training Program in Cancer Biology
|
5T32CA078207-19
|
$554,252
|
|
AARONSON, STUART
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Preclinical analyses of advanced prostate cancer in genetically-engineered mice
|
2R01CA173481-06
|
$385,883
|
$127,341
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S1
|
$120,000
|
$6,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S2
|
$60,000
|
$3,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S3
|
$118,652
|
$5,933
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S4
|
$199,541
|
$9,977
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-43
|
$3,792,720
|
$189,636
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Molecular mechanisms of prostate cancer metastasis
|
5R01CA183929-03
|
$366,000
|
$366,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Evaluation of an OCA2 enhancer variant as a modifier of the phenotype of BAP1-Tumor predisposition syndrome
|
1R21CA219884-01A1
|
$203,471
|
|
ABDEL-RAHMAN, MOHAMED
|
OHIO STATE UNIVERSITY
|
|
Role of NFxB/HIF2a axis in renal cell carcinoma progression
|
5K08CA178168-05
|
$175,163
|
$87,582
|
ABEL, E
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
Master Regulatory MicroRNAs in Glioblastoma
|
5U01CA220841-02
|
$452,813
|
|
ABOUNADER, ROGER
|
UNIVERSITY OF VIRGINIA
|
|
Mechanisms Underlying Functional Programs of Tumor-Associated Macrophages
|
5R01CA172105-03
|
$401,456
|
$401,456
|
ABRAMS, SCOTT
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-09
|
$461,999
|
$461,999
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-10
|
$461,172
|
$461,172
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Center for Multiple Myeloma Nanotherapy
|
3U54CA199092-03S1
|
$29,864
|
$17,022
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Center for Multiple Myeloma Nanotherapy
|
5U54CA199092-03
|
$2,224,884
|
$1,268,184
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Center for Multiple Myeloma Nanotherapy
|
5U54CA199092-04
|
$2,184,301
|
$1,245,052
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Nanoparticle mediated microenvironmental targeting of CCL3 signaling for the treatment of acute myelogenous leukemia
|
1F31CA228391-01
|
$42,418
|
|
ACKUN-FARMMER, MARIAN
|
UNIVERSITY OF ROCHESTER
|
|
WalkIT: Neighborhood walkability and moderation of adaptive walking interventions
|
5R01CA198915-04
|
$568,727
|
|
ADAMS, MARC
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Giant Macrophage-like Cells as a blood-based Biomarker for Lung Cancer Recurrence
|
5R43CA206840-02
|
$67,150
|
|
ADAMS, DANIEL
|
CREATV MICROTECH, INC.
|
|
Discovery and Characterization of Mutations in Breast and Ovarian Cancers
|
5R50CA211280-03
|
$215,047
|
|
ADAMSON, AARON
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Genetic identification of novel mTORC1 regulators and homeostatic signaling mechanisms
|
1F31CA228241-01
|
$44,524
|
|
ADELMANN, CHARLES
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
Probing the role of the IRE1alpha-XBP1 pathway in normal and malignant hematopoiesis
|
5K22CA218467-02
|
$192,575
|
|
ADORO, STANLEY
|
CASE WESTERN RESERVE UNIVERSITY
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
|
5U54CA163069-07
|
$1,414,315
|
$268,720
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
|
5U54CA163069-08
|
$1,347,488
|
$256,023
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
Developing targeted activatable peptides to amplify radiosensitizer delivery
|
5R03CA219744-02
|
$77,500
|
|
ADVANI, SUNIL
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
Plumbagin in Combination with Vemurafenib for BRAF-mutant Melanoma
|
1R03CA212798-01
|
$74,250
|
$37,125
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Novel Combinatorial Therapeutic Approach for Prostate Cancer
|
1R03CA219336-01
|
$74,250
|
$37,125
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Platelets promote growth of ovarian cancer
|
5R01CA177909-05
|
$332,000
|
$166,000
|
AFSHAR-KHARGHAN, VAHID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
ANALYSIS AND THERAPEUTIC TARGETING OF BREAST CANCER DISSEMINATED TUMOR CELLS
|
5R01CA172623-05
|
$384,803
|
$384,803
|
AFT, REBECCA
|
WASHINGTON UNIVERSITY
|
|
High Throughput Mechanical Modulatory Assay for Breast Cancer Drug Testing
|
5R21CA210126-02
|
$207,928
|
$207,928
|
AGAH, MASOUD
|
VIRGINIA POLYTECHNIC INST AND ST UNIV
|
|
New Roles for the WTX Tumor Suppressor and Endocytosis in WNT signaling
|
1F31CA228289-01
|
$34,190
|
|
AGAJANIAN, MEGAN
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer
|
5K08CA218420-02
|
$177,120
|
|
AGUIRRE, ANDREW
|
DANA-FARBER CANCER INST
|
|
Epigenetic and microenvironmental regulation of dormant disseminated cancer
|
1R01CA218024-01
|
$445,511
|
$222,756
|
AGUIRRE-GHISO, JULIO
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Functional Determinants of Metastatic Dormancy
|
5R01CA109182-14
|
$428,739
|
$428,739
|
AGUIRRE-GHISO, JULIO
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-02
|
$474,276
|
$156,511
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-03
|
$470,573
|
$155,289
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Mutagenesis and migration in glioblastoma cells
|
1R21CA220111-01A1
|
$179,240
|
|
AHN, EUN HYUN
|
UNIVERSITY OF WASHINGTON
|
|
Clinical translation of 19F MRI to visualize cancer immunotherapeutic cells
|
5R01CA134633-06
|
$535,071
|
|
AHRENS, ERIC
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
Mapping cancer micro-environments for acute leukemia
|
5R01CA202025-03
|
$455,870
|
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Post-translational control of cancer cell stress response and metastasis
|
5R01CA202027-02
|
$459,505
|
$459,505
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Integrated analysis of protein expression data from the Reverse Phase Protein Array (RPPA) platform
|
5U24CA210950-03
|
$279,908
|
|
AKBANI, REHAN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
MULTIMODAL PRECLINICAL CANCER IMAGING AND THERAPY RESEARCH SPECIALIST
|
5R50CA211481-04
|
$170,003
|
|
AKERS, WALTER
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Validation of a Room-Temperature Storage Technique for Plasma/Serum Biospecimens
|
5R33CA204510-03
|
$338,767
|
|
AKSAN, ALPTEKIN
|
UNIVERSITY OF MINNESOTA
|
|
Cancer Prevention and Control Health Disparities Training Program
|
5T32CA078447-18
|
$161,530
|
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
A collaborative structural hub to promote Cancer Center science and drug design
|
5R50CA211440-03
|
$145,562
|
|
ALESHIN, ALEXANDER
|
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
|
|
Modulation of wild type and mutant p53 by HMGA1
|
1F32CA221010-01A1
|
$58,654
|
|
ALEXANDER, KATHERINE
|
UNIVERSITY OF PENNSYLVANIA
|
|
p63 as a novel factor promoting pregnancy-induced HER2-positive breast cancer
|
5K22CA190653-03
|
$157,743
|
|
ALEXANDROVA, EVGUENIA
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
Development of novel gallium-68 bisphosphonate for imaging bone metastases in prostate cancer
|
1R43CA221580-01
|
$225,000
|
$225,000
|
ALEXOFF, DAVID
|
FIVE ELEVEN PHARMA, INC.
|
|
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
|
5F30CA220847-02
|
$49,524
|
|
ALI, MOIEZ
|
DUKE UNIVERSITY
|
Total relevant funding to Metastasis for this search: $548,390,062
|